Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$0.96
-2.1%		$1.13
$0.76
▼
$3.31
$76.55M1.491.03 million shs481,026 shs
Pluri Inc. stock logo
PLUR
Pluri
$1.59
-4.5%		$1.92
$1.45
▼
$5.68
$17.93M0.6720,723 shs2,989 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.26
+3.7%		$1.20
$1.02
▼
$1.88
$64.80M1.34307,718 shs189,817 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.30
-1.3%		$2.31
$2.09
▼
$3.61
$71.04M0.8436,027 shs46,499 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-0.66%+2.46%-24.89%-41.08%-59.84%
Pluri Inc. stock logo
PLUR
Pluri
+0.92%-9.39%-2.38%-51.34%-65.40%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-3.57%+2.97%-14.44%-5.81%-20.07%
XBiotech Inc. stock logo
XBIT
XBiotech
-5.28%+2.19%+1.75%-5.28%-25.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$0.96
-2.1%		$1.13
$0.76
▼
$3.31
$76.55M1.491.03 million shs481,026 shs
Pluri Inc. stock logo
PLUR
Pluri
$1.59
-4.5%		$1.92
$1.45
▼
$5.68
$17.93M0.6720,723 shs2,989 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.26
+3.7%		$1.20
$1.02
▼
$1.88
$64.80M1.34307,718 shs189,817 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.30
-1.3%		$2.31
$2.09
▼
$3.61
$71.04M0.8436,027 shs46,499 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-0.66%+2.46%-24.89%-41.08%-59.84%
Pluri Inc. stock logo
PLUR
Pluri
+0.92%-9.39%-2.38%-51.34%-65.40%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-3.57%+2.97%-14.44%-5.81%-20.07%
XBiotech Inc. stock logo
XBIT
XBiotech
-5.28%+2.19%+1.75%-5.28%-25.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.14
Hold$7.50678.82% Upside
Pluri Inc. stock logo
PLUR
Pluri
1.00
SellN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
2.75
Moderate Buy$4.00217.46% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest PLUR, XBIT, CRDF, and PMVP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
8/11/2026
Pluri Inc. stock logo
PLUR
Pluri
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/5/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/28/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/23/2026
Pluri Inc. stock logo
PLUR
Pluri
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/21/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/10/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/8/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.00
7/7/2026
Pluri Inc. stock logo
PLUR
Pluri
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/30/2026
XBiotech Inc. stock logo
XBIT
XBiotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$590K126.97N/AN/A$0.34 per share2.83
Pluri Inc. stock logo
PLUR
Pluri
$1.34M12.78N/AN/A($0.11) per share-14.43
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/A$1.97 per shareN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/A$4.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.85M-$0.67N/AN/AN/A-7,885.43%-103.10%-75.52%10/29/2026 (Estimated)
Pluri Inc. stock logo
PLUR
Pluri
-$22.58M-$4.53N/AN/AN/A-2,162.08%N/A-106.59%9/23/2026 (Estimated)
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$77.74M-$1.49N/AN/AN/AN/A-68.98%-62.70%N/A
XBiotech Inc. stock logo
XBIT
XBiotech
-$45.54M-$1.48N/AN/AN/AN/A-30.60%-29.28%N/A

Latest PLUR, XBIT, CRDF, and PMVP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.3875-$0.34+$0.0475-$0.34N/AN/A
8/13/2026Q2 2026
XBiotech Inc. stock logo
XBIT
XBiotech
$0.03-$0.22-$0.25-$0.22$7.00 millionN/A
8/11/2026Q2 2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.1196-$0.14-$0.0204-$0.14$0.06 million$0.10 million
5/14/2026Q1 2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.13-$0.18-$0.05-$0.18$0.09 million$0.04 million
5/14/2026Q3 2026
Pluri Inc. stock logo
PLUR
Pluri
-$0.66-$0.55+$0.11-$0.55$0.66 million$0.17 million
5/14/2026Q1 2026
XBiotech Inc. stock logo
XBIT
XBiotech
$0.03-$0.18-$0.21-$0.18$7.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Pluri Inc. stock logo
PLUR
Pluri
N/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
3.30
3.27
Pluri Inc. stock logo
PLUR
Pluri
N/A
0.33
0.33
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/A
11.14
11.14
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
39.03
39.03

Institutional Ownership

CompanyInstitutional Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Pluri Inc. stock logo
PLUR
Pluri
16.59%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
90.20%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%

Insider Ownership

CompanyInsider Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
8.50%
Pluri Inc. stock logo
PLUR
Pluri
43.16%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
10.15%
XBiotech Inc. stock logo
XBIT
XBiotech
30.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2077.79 million71.18 millionOptionable
Pluri Inc. stock logo
PLUR
Pluri
15010.79 million6.13 millionNo Data
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
5053.33 million47.92 millionOptionable
XBiotech Inc. stock logo
XBIT
XBiotech
10030.49 million21.10 millionOptionable

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS
August 13 at 5:10 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xbiotech-nasdaqxbit-issues-quarterly-earnings-results-misses-estimates-by-025-eps-2026-08-13/
XBiotech (NASDAQ:XBIT) Share Price Crosses Below 200-Day Moving Average - What's Next?
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xbiotech-nasdaqxbit-share-price-crosses-below-200-day-moving-average-whats-next-2026-07-30/
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311812/35550/en/xbiotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug-for-the-treatment-of-active-axial-spondyloarthritis.html
XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar
May 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xbiotechs-new-axial-spondyloarthritis-trial-puts-vilamakitug-on-investors-radar?utm_source=marketbeat.com&utm_medium=referral
XBiotech: Q4 Earnings Snapshot
March 13, 2026  |  chron.comhttps://www.chron.com/business/article/xbiotech-q4-earnings-snapshot-22075535.php
XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?
October 28, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/xbiotech-s-new-trial-a-potential-game-changer-for-rheumatoid-arthritis-treatment/ar-AA1PitPW
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders
August 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/xbiotech-inc-nasdaq-xbit-top-100425873.html
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
March 2, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
March 1, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 28, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 27, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 26, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 25, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 24, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 23, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 22, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 21, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 20, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 18, 2025  |  accessnewswire.comA
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 17, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 16, 2025  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$0.96 -0.02 (-2.13%)
Closing price 04:00 PM Eastern
Extended Trading
$1.00 +0.04 (+3.84%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Pluri stock logo

Pluri NASDAQ:PLUR

$1.59 -0.07 (-4.48%)
Closing price 03:58 PM Eastern
Extended Trading
$1.62 +0.03 (+1.76%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

PMV Pharmaceuticals stock logo

PMV Pharmaceuticals NASDAQ:PMVP

$1.26 +0.05 (+3.70%)
Closing price 04:00 PM Eastern
Extended Trading
$1.26 0.00 (0.00%)
As of 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$2.30 -0.03 (-1.29%)
Closing price 03:59 PM Eastern
Extended Trading
$2.33 +0.03 (+1.30%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas